SynCardia Systems Appoints Rodger G. Ford to Board of Directors
Entrepreneur and Business Leader to Provide Strategic Counsel on the Continued Development and Marketing
of the CardioWest™ temporary Total Artificial Heart
TUCSON, Ariz. – May 11, 2004 – SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, announced today the appointment of Rodger G. Ford to its Board of Directors.
Mr. Ford brings more than 30 years of entrepreneurial accomplishments and leadership to the SynCardia Board, having founded AlphaGraphics Print Shops of the Future and Anthem Equity Group, Inc. Under Mr. Ford’s leadership, AlphaGraphics grew to more than 400 locations worldwide, with franchises in Canada, South America, Australia, Europe and the Middle East. At Anthem Equity Group, which develops and operates office and industrial real estate, Mr. Ford in responsible for new business opportunities and venture investing. Mr. Ford has served on Boards for numerous organizations and was named Ernst & Young Entrepreneur of the Year in 2000.
“Rodger’s leadership, vision and experience in growing successful companies makes him an invaluable resource for SynCardia. This is exciting time for SynCardia as the CardioWest™ temporary Total Artificial Heart continues on course to become the world’s first FDA-approved total artificial heart,” said Dr. Marvin Slepian, president and CEO, SynCardia. “We look forward to his strategic counsel as SynCardia moves into the next state of corporate growth both in the United States and in Europe, where the CardioWest™ TAH-t is already available.”
“The market potential for the CardioWest™ temporary Total Artificial Heart is tremendous and I am pleased to provide SynCardia’s Board of Directors and executive team with guidance and support at this exciting juncture,” said Rodger Ford.
SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,350 implants of the SynCardia Total Artificial Heart accounts for over 400 patient years of life on the device. Since January 2011 more than 400 SynCardia Hearts have been implanted.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to leave the hospital to live at home and in their communities. The wearable Freedom driver has been used by 190 patients, accounting for over 110 years of support.